Sunday October 21, 2018

Addyi: an antidepressant, not female Viagra

0
//
156
Republish
Reprint

25FactsAboutFlibanserin  By NewsGram Staff Writer

While sexual problems remain a more clandestine affair for women than men, a respite in the name of Addyi has been introduced. This pink pill can pull out women from their depression which is caused due to their sexual inactivity.

With the US FDA giving a green signal to Flibanserin, commonly known as Addyi, the pharmaceutical industry has received its first drug which can treat a flagging or absent libido in women.

Addyi is erroneously being called as the “female Viagra”. However, that is not the case! While Viagra treats erectile dysfunction and focuses on the genitals of a man, Addyi works on the central nervous system, thereby targeting the brain and not the genitals.

Sprout Pharmaceuticals, the manufacturer of this pill won the FDA approval after two consecutive rejections in the year 2010 and 2013 respectively. The approval of Addyi is accompanied by various side-effects and caveat. Since Addyi targets the brain, it is classified under the category of antidepressants.

This drug comes with side-effects that include dizziness, nausea, fatigue and somnolence. While Viagra is a pill that men take before a sexual encounter, Addyi needs to be taken everyday. Moreover, this pill can be prescribed only by doctors and apothecaries who watch an online presentation and pass a test related to it.

lady-viagra

This prescription of this drug doesn’t entail that the woman is ill or is undergoing some relationship problems. Instead, this pill is dispensed for women whose loss of sexual desire causes marked distressed or depression in some cases.

While Dr Lauren Streicher, associate professor of clinical obstetrics and gynecology at Northwest University believes that this pill will induce women to talk about their sexual problems, Adriane Fugh-Berman, a pharmacology professor and director of PharmedOut thinks that such drugs open way for other “bad drugs” to enter into the market.

Click here for reuse options!
Copyright 2015 NewsGram

Next Story

First Self-Assisted Hearing Aid Approved by The FDA

The FDA reviewed data from clinical studies of 125 patients, showing that outcomes with self-fitting of the device are comparable on average to those with a professional fitting of the same device

0
FDA
An 85-year-old Nepalese man is seen fitted with a hearing aid, in Kathmandu, Nepal, April 12, 2017. VOA

The US Food and Drug Administration (FDA) on Friday allowed the marketing of a new hearing aid device that can amplify sounds for individuals 18 years or older with perceived mild to moderate hearing loss.

It is the first hearing aid approved by the agency that enables users to fit, programme and control the hearing aid on their own, without assistance from a health care provider, Xinhua news agency reported.

FDA
www.fdalawyersblog.com

Hearing loss, permanent or temporary, can be caused by aging, exposure to loud noises, certain medical conditions and other factors. Individuals with permanent hearing loss can use hearing aids to help them hear the speech and sounds.

The Bose Hearing Aid is a user-fitted wireless air conduction hearing aid, according to FDA.

Air conduction hearing aids can capture sound vibrations through one or more microphones and the signal is processed, amplified, and played back through an earphone placed in the ear canal.

FDA
A hearing aid (representative Image). Wikimedia

Patients can adjust the hearing aid through a mobile application on their phone. This technology enables users to fit the hearing aid settings themselves, in real-time and in real-world environments without the assistance of a health care professional.

Also Read: Eat Right Amount of Good Fat to Stay Healthy

The FDA reviewed data from clinical studies of 125 patients, showing that outcomes with self-fitting of the device are comparable on average to those with professional fitting of the same device with respect to the amount of amplification selected, speech in noise testing and overall benefit. (IANS)

Next Story